A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

In patients with peritoneal metastases of gastric and ovarian cancer, the addition of concomitant intraperitoneal chemotherapy to systemic chemotherapy showed promising results. This study will ...